Chelsea's Stock Plummets on Shaky Parkinson's Data
By Catherine Shaffer
Thursday, February 3, 2011
Stock in Chelsea Therapeutics International Ltd. tumbled 18.5 percent on Wednesday after the company reported that an interim analysis had found their Phase III (306) trial of Northera (droxidopa) for neurogenic orthostatic hypotension (NOH) in Parkinson's patients to be futile.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.